New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 21, 2013
05:37 EDTAZNAstraZeneca enters into integrated alliance with Evotec, terms not disclosed
Evotec AG announced that it has signed an agreement with AstraZeneca in the field of kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. Under the terms of this licence and collaboration agreement, AstraZeneca will receive access to a selected series of molecules identified in a screening effort, which is part of Evotec's systematic kidney disease initiative. This particular programme has been designed to explore a key mechanism in the field of chronic kidney disease. AstraZeneca will provide industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities. The agreement between Evotec and AstraZeneca triggers an undisclosed upfront payment as well as pre-clinical, clinical and regulatory milestones. Evotec is also eligible for additional milestone and royalty payments related to commercialisation. Evotec will receive research funding for work that will be conducted in collaboration with AstraZeneca. Specific financial details were not disclosed.
News For AZN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
06:24 EDTAZNAstraZeneca turning antibiotic R&D into separate subsidiary, Reuters reports
Subscribe for More Information
February 23, 2015
12:53 EDTAZNAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
07:55 EDTAZNJefferies says other bidders may emerge for Salix
Jefferies says it could envision other bidders emerging for Salix (SLXP) and points out recent media reports have suggested Shire (SHPG) and Endo (ENDP) have considered making a bid for the company. It lists AstraZeneca (AZN) and Takeda as others who could have possible interest in Salix. The firm believes Valeant (VRX) could afford to pay more for Salix should other bidders emerge.
February 20, 2015
07:23 EDTAZNAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTAZNAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
February 17, 2015
17:16 EDTAZNActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
February 13, 2015
16:32 EDTAZNActavis launches generic Pulmicort RESPULES
Subscribe for More Information
08:19 EDTAZNAckman noncommittal on McDonald's rumors, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use